Remove 2006 Remove DNA Remove Small Molecule
article thumbnail

The evolution of cell therapy to address unmet medical needs

Drug Target Review

The other powerful benefit is that our cell lines can become any of the cell types of the human body – these cells have within their DNA the capability to become any of the more than 200 human cell types which you might want to manufacture. Just like small molecules and antibodies, cell therapies are changing how we treat patients.

article thumbnail

Evaluating Impurities in New Drugs to Prevent Delays in Development

The Premier Consulting Blog

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. In addition, this guidance focuses on DNA reactive substances that could potentially cause cancer. Global regulatory agencies, including the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Targeted Cancer Drugs Disrupt the Cell Cycle

PLOS: DNA Science

A “DNA damage checkpoint” rests the cell cycle while special proteins repair damaged DNA. The candidate drug, vorasidenib, is a small molecule that inhibits survivin. I had the privilege to meet one of the first people to receive Gleevec, which I wrote about for Bioethics Today in 2006.

Drugs 52
article thumbnail

Defense-Forward Biosecurity

Codon

Allison Berke makes the case for real-time DNA sequencing and AI tools to detect pathogens before they spread widely. Reading DNA The first step in detecting a novel pathogen is recognizing it as an anomaly amidst a noisy background of other material. After copying the DNA to form a big pool, each piece is sequenced.

DNA 111
article thumbnail

Antibody-drug conjugates payloads: then, now and next

Drug Target Review

2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Florian S, Mitchison TJ.